Company / Cash & Equivalents
Relay Therapeutics, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$84.0M
FY2025
5-year range
$84.0M / $447.6M
FY2021-FY2025
Trend
-32.4%
vs FY2024
Sector context
#155 of 207
Health Care
What the data says
Relay Therapeutics, Inc.'s cash & equivalents of $84M is lower than 75% of companies in the Health Care sector (FY2025). Cash & Equivalents has declined for 4 consecutive years, from $448M in FY2021 to $84M in FY2025.
Based on SEC 10-K filings.
$84M in FY2025 with a 5-year CAGR of +14.9%.
Declined from $144M to $84M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.9%
- 5-Year CAGR
- +14.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 207This company $84.0M Sector average $669.5M
▼
-87.5% below sector average
Key checks
Key Insights
- Relay Therapeutics, Inc.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of +14.9%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 32.4% year-over-year.
- Ranks #155 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $84.0M | -32.4% |
| FY2024 | $124.3M | -13.5% |
| FY2023 | $143.7M | -5.3% |
| FY2022 | $151.8M | -66.1% |
| FY2021 | $447.6M | +967.0% |
| FY2020 | $42.0M | +0.0% |
| FY2019 | $42.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026